tiprankstipranks
Sumitomo Dainippon Pharma Co Ltd (DNPUF)
OTHER OTC:DNPUF
Holding DNPUF?
Track your performance easily

Sumitomo Dainippon Pharma Co (DNPUF) Stock Forecast & Price Target

7 Followers
See the Price Targets and Ratings of:

DNPUF Analyst Ratings

Moderate Sell
1Ratings
0 Buy
0 Hold
1 Sell
Based on 1 analysts giving stock ratings to
Sumitomo
Dainippon Pharma Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DNPUF Stock 12 Month Forecast

Average Price Target

$2.99
▼(-21.32% Downside)
Based on 1 Wall Street analysts offering 12 month price targets for Sumitomo Dainippon Pharma Co in the last 3 months. The average price target is $2.99 with a high forecast of $2.99 and a low forecast of $2.99. The average price target represents a -21.32% change from the last price of $3.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","2":"$2","3":"$3","4":"$4","5":"$5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.9856162,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.99,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.9856162,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.99</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2,3,4,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.62,3.571201246153846,3.5224024923076924,3.4736037384615384,3.4248049846153847,3.3760062307692307,3.327207476923077,3.278408723076923,3.2296099692307694,3.1808112153846153,3.1320124615384617,3.0832137076923076,3.034414953846154,{"y":2.9856162,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.62,3.5715384615384616,3.523076923076923,3.474615384615385,3.4261538461538463,3.3776923076923078,3.329230769230769,3.280769230769231,3.2323076923076925,3.183846153846154,3.1353846153846154,3.0869230769230773,3.0384615384615388,{"y":2.99,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.62,3.571201246153846,3.5224024923076924,3.4736037384615384,3.4248049846153847,3.3760062307692307,3.327207476923077,3.278408723076923,3.2296099692307694,3.1808112153846153,3.1320124615384617,3.0832137076923076,3.034414953846154,{"y":2.9856162,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.2,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.26,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.42,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.4,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.68,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.54,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.16,"date":1715904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1717718400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1720137600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1722556800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1725580800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1728000000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$2.99Average Price Target$2.99Lowest Price Target$2.99
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$4.87
Hold
28.10%
Upside
Reiterated
08/26/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Telix Pharmaceuticals Ltd. (Other OTC: TLPPF), Sumitomo Dainippon Pharma Co (Other OTC: DNPUF) and CSPC Pharmaceutical Group (Other OTC: CHJTF)
J.P. Morgan
$1.62$3.25
Hold
-14.60%
Downside
Upgraded
08/16/24
JPMorgan Upgrades Sumitomo Pharma (4506:JP) (DNPUF) to NeutralJPMorgan analyst Naomi Kumagai upgraded Sumitomo Pharma (4506:JP) (OTC: DNPUF) from Underweight to Neutral with a price target of JPY500.00 (from JPY250.00).
UBS
$2.4
Sell
-36.80%
Downside
Downgraded
07/24/24
UBS Downgrades Sumitomo Pharma (4506:JP) (DNPUF) to SellUBS analyst Fumiyoshi Sakai downgraded Sumitomo Pharma (4506:JP) (OTC: DNPUF) from Neutral to Sell with a price target of JPY370.00.

Best Analysts Covering Sumitomo Dainippon Pharma Co

Which Analyst Should I Follow If I Want to Buy DNPUF and Sell After:
1 Month
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+1.00%
downgraded a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +1.00% per trade.
3 Months
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+1.00%
downgraded a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +1.00% per trade.
1 Year
Success Rate
1/1 ratings generated profit
100%
Average Return
+1.00%
downgraded a sell rating last month
Copying Hidemaru Yamaguchi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +1.00% per trade.
2 Years
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+1.00%
downgraded a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +1.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DNPUF Analyst Recommendation Trends

Rating
Sep 21
May 24
Jul 24
Aug 24
Oct 24
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
0
1
1
4
3
Sell
3
2
2
1
2
Strong Sell
0
0
0
0
0
total
3
3
3
5
5
In the current month, DNPUF has received 0 Buy Ratings, 3 Hold Ratings, and 2 Sell Ratings. DNPUF average Analyst price target in the past 3 months is $2.99.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

DNPUF Financial Forecast

DNPUF Earnings Forecast

Next quarter’s earnings estimate for DNPUF is $0.27 with a range of $0.27 to $0.27. The previous quarter’s EPS was -$0.78. DNPUF beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.91% of the time in the same period. In the last calendar year DNPUF has Underperformed its overall industry.
Next quarter’s earnings estimate for DNPUF is $0.27 with a range of $0.27 to $0.27. The previous quarter’s EPS was -$0.78. DNPUF beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.91% of the time in the same period. In the last calendar year DNPUF has Underperformed its overall industry.

DNPUF Sales Forecast

Next quarter’s sales forecast for DNPUF is $598.64M with a range of $583.21M to $618.96M. The previous quarter’s sales results were $581.96M. DNPUF beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.68% of the time in the same period. In the last calendar year DNPUF has Outperformed its overall industry.
Next quarter’s sales forecast for DNPUF is $598.64M with a range of $583.21M to $618.96M. The previous quarter’s sales results were $581.96M. DNPUF beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.68% of the time in the same period. In the last calendar year DNPUF has Outperformed its overall industry.

DNPUF Stock Forecast FAQ

What is DNPUF’s average 12-month price target, according to analysts?
Based on analyst ratings, Sumitomo Dainippon Pharma Co Ltd’s 12-month average price target is $2.99.
    What is DNPUF’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for DNPUF, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is DNPUF a Buy, Sell or Hold?
        Sumitomo Dainippon Pharma Co Ltd has a consensus rating of Moderate Sell which is based on 0 buy ratings, 0 hold ratings and 1 sell ratings.
          What is Sumitomo Dainippon Pharma Co Ltd’s price target?
          The average price target for Sumitomo Dainippon Pharma Co Ltd is $2.99. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $2.99 ,the lowest forecast is $2.99. The average price target represents -21.32% Decrease from the current price of $3.8.
            What do analysts say about Sumitomo Dainippon Pharma Co Ltd?
            Sumitomo Dainippon Pharma Co Ltd’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 1 Wall Streets Analysts.
              How can I buy shares of DNPUF?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis